Clinical trials
HIV Infected Individuals clinical trials
Below are recruiting hiv infected individuals clinical trials, each written for real people, not researchers. We’re tracking 72 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06829238RecruitingPhase 4
Metformin to boost immune function in people with a history of drug use
This study tests whether metformin, a common diabetes drug, can help restore immune system balance in people who have used injection drugs in the past. It includes both people living with HIV and those who are HIV-negative.
Birmingham, AlabamaAges 18–64 - NCT06924073Recruiting
Helping young people with HIV move to adult care
This study tests a program to help young people with HIV move from teen to adult care. If you are 10-24 and get HIV care at one of the study clinics, this program may support you during this transition.
AwendoAges 10 years+ - NCT04855773Recruiting
Mobile text-message support to help people stay on PrEP
This trial tests whether phone-based (iPhone/Android) text-message support can improve how consistently people use PrEP, an HIV prevention medicine. It may help you stay on track with refills and clinic visits, especially if you’re at higher risk of stopping PrEP.
San Francisco, CaliforniaAges 15 years+ - NCT07392372RecruitingPhase 1
Testing the safety of BNT351 in people with and without HIV
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
Chicago, IllinoisAges 18–65 - NCT04883255RecruitingEarly Phase 1
Study cannabis effects on brain function in adults with HIV
This early-phase study looks at how cannabis (and the body’s cannabinoid system) may affect thinking and brain-related measures in people with HIV. You may be asked to avoid cannabis and complete several brain and health assessments to see how these factors relate.
San Diego, CaliforniaAges 18–65 - NCT07186244Recruiting
HIV Prevention Study for People Starting or Taking PrEP
This study is for people who are HIV-negative and want to take PrEP (a daily pill that prevents HIV). It will help researchers learn more about how to best support people taking PrEP in real-world settings.
Chieti, AbruzzoAges 18 years+ - NCT06183723Enrolling by invitation
Study to improve HIV care for those struggling with medications
This study tests a program to help people living with HIV who have difficulty taking their medications consistently. The goal is to see if extra support can improve health outcomes.
Kaohsiung CityAges 18 years+ - NCT05488431RecruitingPhase 2
Bempedoic acid to lower cholesterol and inflammation in HIV
This Phase 2 trial studies whether bempedoic acid can lower cholesterol and inflammation in people with HIV who are already on effective HIV medications. It may help reduce signs of artery inflammation that can contribute to heart and stroke risk.
Los Angeles, CaliforniaAges 40 years+ - NCT06337032RecruitingPhase 4
Continued access to HIV treatment for children and teens
This trial provides continued access to Biktarvy (B/F/TAF) for children and adolescents who completed a previous Gilead HIV study. It ensures they can keep taking the medication without interruption.
Buenos AiresAges 1 month+ - NCT04174755Recruiting
Semaglutide for weight loss in adults with HIV
This trial studies whether semaglutide (a diabetes-type weight-loss injection) helps adults with HIV lose weight. It also checks that it’s safe for people whose HIV is well controlled on regular treatment.
Dublin, DublinAges 18 years+ - NCT07202546RecruitingPhase 2
New oral HIV drug trial for people new to treatment
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
Bakersfield, CaliforniaAges 18 years+ - NCT06103370Recruiting
HIV prevention via telemedicine and peer networks
This study tests how well a program combining telemedicine (virtual doctor visits) and peer support can help prevent HIV among people who inject drugs. You'd get trained, attend weekly group sessions, and invite a friend or partner to also take part.
Baltimore, MarylandAges 18 years+ - NCT07342491RecruitingPhase 1
Testing dasatinib to shrink HIV reservoir
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
Chicago, IllinoisAges 18 years+ - NCT03684655RecruitingPhase 2
PET-MR scan study of immune activity in people with HIV
This Phase 2 study uses a special whole-body scan (PET-MR) to measure immune activity in people living with HIV. It may help researchers understand how well the immune system responds and how to better track HIV-related inflammation.
San Francisco, CaliforniaAges 18 years+ - NCT05187429RecruitingPhase 1/Phase 2
Low-dose nivolumab for adults with HIV on stable therapy
This trial tests whether a low dose of nivolumab can safely affect the immune system in adults living with HIV who are already on stable HIV treatment. You may benefit by helping researchers understand a new approach, but the main goal is to check safety and early effectiveness.
Melbourne, VictoriaAges 18–65 - NCT05373758Recruiting
Help for people whose HIV treatment is not working
This trial tests different ways to manage “virologic failure,” meaning HIV viral load stays high while taking TLD (a common HIV medicine combination). It may help people better control the virus and improve treatment results, especially in parts of sub-Saharan Africa.
DurbanAges 15 years+ - NCT07481175RecruitingPhase 1
Testing a drug to reduce hidden HIV early after treatment start
This trial tests whether adding venetoclax, a drug that helps infected cells die, at the start of HIV treatment can lower the amount of hidden virus that stays in the body. It may help reduce the HIV reservoir.
AarhusAges 18–70 - NCT07682961RecruitingPhase 3
Study of new HIV injection vs. standard injectables
This phase 3 trial tests a new long-acting, injectable two-drug combination (lenacapavir + teropavimab + zinlirvimab) vs. another injectable combo (cabotegravir + rilpivirine) for people whose HIV is already well-controlled on daily oral meds. It aims to see if the new combo can keep the virus under control with fewer injections.
Fort Lauderdale, FloridaAges 18 years+ - NCT05026723Recruiting
Food plan to improve health for HIV and type 2 diabetes
This study tests whether a personalized “food as medicine” approach can help people manage health related to HIV and type 2 diabetes or prediabetes risk. If you struggle with having enough healthy food, the program may focus on practical ways to improve diet and support healthier blood sugar.
Chapel Hill, North CarolinaAges 18 years+ - NCT06205602RecruitingPhase 2
HIV treatment with antibodies for a cure in Africa
This study tests if giving antibodies along with standard HIV medications can help control the virus without daily pills. It may lead to a functional cure for people living with HIV.
GaboroneAges 18–60 - NCT07293559Recruiting
Understanding infant feeding choices in women with HIV
This study looks at how women with HIV decide whether to breastfeed, and what support they get from healthcare providers and family. It aims to learn about their experiences and needs.
Los Angeles, CaliforniaAges Any age - NCT06055868Recruiting
HIV, oral cancer, and health equity study
This study looks at the experiences of people living with HIV who also have oral or throat cancer. The goal is to understand health disparities and improve care.
San Francisco, CaliforniaAges 18 years+ - NCT03729752RecruitingPhase 1
PET scan to study an HIV-fighting antibody in the body
This Phase 1/early study uses a special PET scan to see where an HIV-targeting antibody (VRC01) goes in the body. The study may help researchers understand how well this antibody reaches HIV-related targets, which could guide future HIV treatments or vaccines.
San Francisco, CaliforniaAges 18 years+ - NCT07683000RecruitingPhase 3
Study of three HIV drugs for adults with controlled HIV
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
Berkeley, MichiganAges 18 years+
Hear when a new HIV Infected Individuals trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv infected individuals?
- Yes. Clin2 currently lists 72 recruiting hiv infected individuals studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv infected individuals trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv infected individuals trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.